Microsoft Restores Microsoft 365 Services After Widespread Outage 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
SoftBank Shares Surge as AI Optimism Lifts Asian Tech Stocks 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Elon Musk Shares Bold Vision for AI, Robots, and Space at Davos 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
CAMBRIDGE, Mass., May 10, 2017 -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
Bank of America Merrill Lynch 2017 Health Care Conference
Wednesday, May 16, 2017 at 12:20 p.m. ET in Las Vegas, NV
UBS Global Healthcare Conference
Tuesday, May 23, 2017 at 9:00 a.m. ET in New York, NY
A webcast of each presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of each presentation will be posted on the Momenta website approximately one hour after each event.
About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.
Contact: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 [email protected]
